Research Analysts’ Weekly Ratings Changes for Palvella Therapeutics (PVLA)

A number of firms have modified their ratings and price targets on shares of Palvella Therapeutics (NASDAQ: PVLA) recently:

• 2/25/2026 – Palvella Therapeutics had its price target raised by Mizuho from $205.00 to $250.00. They now have an “outperform” rating on the stock.
• 2/25/2026 – Palvella Therapeutics had its price target raised by BTIG Research from $192.00 to $215.00. They now have a “buy” rating on the stock.
• 2/24/2026 – Palvella Therapeutics was given a new $210.00 price target by Truist Financial Corporation.
• 2/24/2026 – Palvella Therapeutics was given a new $250.00 price target by Stifel Nicolaus.
• 2/24/2026 – Palvella Therapeutics had its price target raised by HC Wainwright from $200.00 to $255.00. They now have a “buy” rating on the stock.
• 2/24/2026 – Palvella Therapeutics had its price target raised by Chardan Capital from $174.00 to $210.00. They now have a “buy” rating on the stock.
• 2/2/2026 – Palvella Therapeutics had its “buy” rating reaffirmed by TD Cowen.
• 1/29/2026 – Palvella Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $192.00 price target on the stock.
• 1/16/2026 – Palvella Therapeutics had its “buy” rating reaffirmed by BTIG Research. They now have a $192.00 price target on the stock.

Insider Buying and Selling

In related news, COO Kathleen Goin sold 4,302 shares of the firm’s stock in a transaction that occurred on Wednesday, January 21st. The shares were sold at an average price of $97.63, for a total value of $420,004.26. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Elaine J. Heron bought 2,400 shares of the stock in a transaction that occurred on Friday, February 27th. The stock was bought at an average price of $125.00 per share, with a total value of $300,000.00. Following the completion of the acquisition, the director owned 47,812 shares of the company’s stock, valued at $5,976,500. This trade represents a 5.28% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. 20.50% of the stock is currently owned by company insiders.

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.